


ORIGINAL RESEARCH

Open Access



Nasal nalbuphine analgesia in prehospital trauma managed by first-responder personnel on ski slopes in Switzerland: an observational cohort study

Urs Pietsch^{1,2,3*} , Yoël Berger⁴, David Schurter⁵, Lorenz Theiler⁶, Volker Wenzel⁷, Lorenz Meuli⁸, Andreas Grünenfelder⁹ and Roland Albrecht^{1,2,3}

Abstract

Background: Pain is one of the major symptoms complained about by patients in the prehospital setting, especially in the case of trauma. When there is mountainous topography, as in Switzerland, there may be a time delay between injury and arrival of professional rescuers, in particular on ski slopes. Administration of a safe opioid by first responders may improve overall treatment. We therefore assessed administration of nasal nalbuphine as an analgesic treatment for trauma patients in Switzerland.

Methods: This observational cohort study examined 267 patients who were treated with nasal nalbuphine by first responders in six ski resorts in Switzerland. All first responders were instructed to begin treatment by assessing the feasibility of using nalbuphine to treat pain in the patient. A treatment algorithm was developed and distributed to assure that nalbuphine was only administered following a strict protocol. Data regarding pain scores and pain reduction after administration of nalbuphine were collected on-site. Refills were handed out to the first responders with the return of each completed questionnaire.

Results: Nalbuphine provided effective pain relief, with the median level of pain on the numeric rating scale for pain reduced by 3 units on average, from 8 points ($p < 0.001$). The multivariate regression model showed that pain reduction was more pronounced in patients with higher initial pain levels. Nalbuphine was more effective in adolescents than in patients aged 20 to 60 years ($p = 0.006$). No major side effects were observed.

Conclusion: Nasal administration of nalbuphine by first responders is a presumably safe and effective noninvasive pain management strategy for acutely injured patients in the prehospital setting. This may be an alternative, especially in the case of severe pain and prolonged time between arrival of the first responders and arrival of EMS/ HEMS personnel on scene.

Keywords: Nalbuphine, Prehospital analgesia, Trauma, Emergency medicine, Pain, Wilderness medicine

* Correspondence: urs.pietsch@kssg.ch

¹Department of Anaesthesiology and Intensive Care Medicine, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, 9007 St. Gallen, Switzerland

²Swiss Air-Ambulance, Rega (Rettungsflugwacht / Garde Aérienne), Zürich, Switzerland

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Pain is one of the major prehospital symptoms and requires prompt management, in particular in trauma patients. Nevertheless, many colleagues report that analgesia in the field is insufficient for multiple reasons, one being the overly long response times of the emergency medical service (EMS) [1–5]. In Switzerland, EMS units are staffed with ALS-qualified paramedics, but due to mountainous and alpine terrain, the time until arrival at the scene can be prolonged [6–9]. Therefore, Switzerland also has a long history of helicopter emergency services (HEMS), staffed with a pilot, a paramedic and an ALS-qualified emergency physician. Usually, a given HEMS service can reach every point in Switzerland within 15 min, subject to weather conditions [10].

Winter sports such as downhill skiing and snowboarding attract >2.5 million skiers annually in Switzerland, with about 76,000 injured skiers requiring treatment [11]. First responders in an accident on a ski slope are usually ski lift employees who provide first aid but no analgesia. However, providing analgesia on ski slopes may be achievable with nalbuphine due to its safety features (mixed agonist/antagonist), its ceiling effect regarding respiratory depression, an analgesic potency approximately 0.8 to 0.9 times that of morphine [12], its simple handling and legal approval, its lack of potential for abuse, its safety in pregnant and lactating women, and its potential for use by first responders [13–16, 13, 17, 18].

There are several approved routes of nalbuphine administration, including intravenous (IV), intramuscular (IM), subcutaneous (SC) [13], and nasal, due to nalbuphine's high lipophilicity and low molecular weight [17, 19–21, 22–24]. Because of its simplicity and non-invasive nature, we chose the nasal route for nalbuphine administration by ski slope first responders. Our hypothesis was that nasal nalbuphine would have no effect on pain in victims of ski slope accidents.

Methods

This observational cohort study examined data collected from patients given nalbuphine analgesia by first responders in the prehospital phase. Reporting of the study conforms to the STROBE statement for the reporting of observational cohort studies.

Study design

This analytical observational cohort study was performed in six different ski resorts in the canton of Graubünden, Switzerland (Arosa, Jakobshorn Davos, Lenzerheide, Marguns Engadin, Parsenn, and Weisse Arena Laax). All interested first responders received mandatory theoretical and practical instruction about

nasal nalbuphine using the Mucosal Atomization Device (Teleflex, Wayne, PA, USA). Specifically, they were instructed about the mechanisms of action, indications and contraindications, as well as the potential side effects. Administration of nalbuphine according to an algorithm was required to assure patient safety (Fig. 1). First responders were free to choose to participate and to enrol patients. Therefore, the inclusion of patients was non-consecutive and there was no control group in this study. We report results from experience with nasal administration of nalbuphine from November 2017 until April 2020.

Medication, administration, indications and contraindications


Nalbuphine (Nalbuphin OrPha®, OrPha Swiss, Kuesnacht, Switzerland) in a dose of 10 mg/ml in vials containing 2 ml (20 mg) was used. The dosage was according to body weight, with a minimum dose of 5 mg for patients of 20–44 kg up to a maximum dose of 20 mg for adults >75 kg with severe pain (Fig. 1). The total dosage was divided in half to administer a maximum of 1 ml in each nostril. The main indication for nalbuphine was severe pain, defined as a score of ≥ 5 on a numeric rating scale (NRS), with 0 defined as absence of pain and 10 being the maximum imaginable pain. If there was evidence of altered consciousness, alcohol consumption or noticeable abnormal vital signs, administration of nalbuphine by first responders was deemed contraindicated. Head trauma was an absolute contraindication for nalbuphine regardless of changes in mental status, to assure that no nasal drug was applied as long as a skull fracture was not excluded. Further nalbuphine contraindications were known allergy to the drug or its additives, patient refusal, or body weight < 20 kg. Nalbuphine was also restricted to cases in which it was highly likely that the waiting time until arrival of an EMS or HEMS team was greater than 15 min.

Data collection and statistical analysis

Data collection was performed directly by first responders using an online questionnaire with predefined endpoints (First responders online questionnaire in German; <https://docs.google.com/forms/d/e/1FAIpQLScuvbf0s-n9Ev5EGcO10d9Vw1Gv9JHptJvV1smNeJZy-pTJLA/viewform>). Apart from age and sex, no further personal data were recorded in order to ensure de-identification of patients. Also, no personal data of the first responders on scene were collected, so no conclusions about the rescuers could be drawn during later analysis.

Statistical analysis

Patients' characteristics were summarized and presented in tables. Continuous variables were summarized by



mean ± standard deviation if normally distributed or by median and the interquartile range if skewed. Normality was tested using the Shapiro-Wilk test. Categorical variables were summarized with counts and percentages for each level of the variable. The Wilcoxon-Mann-Whitney-U Test was used to assess differences in pre-

vs. post-nalbuphine NRS. To further elaborate on factors that are potentially associated with the effectiveness of nalbuphine, a multiple linear regression model was built including the variables sex, age in categories and initial pain level in a complete-case analysis. Due to heteroscedasticity of pain reduction depending on the initial

reported pain level, the same regression model was built on a calculated relative pain reduction variable, i.e., percentage of NRS from initial NRS. Dose of nalbuphine applied was excluded from the model due to multicollinearity of this variable, and the initial pain level. Location of injury was not included in the model due to the low number of patients per injury location, and the substantial proportion of missing data for this variable.

Results

Patient characteristics

During the observation period, a total of 267 patients (male sex, 58.8%; age, 33.3 ± 18.2 years) were treated with nasal nalbuphine by first responders (Table 1). The most common part of the body injured were the upper extremities (44.2%), with more than half of these involving the shoulder (23.6% of all injuries). Lower extremities were injured in 35.2%, with a majority of knee and lower leg injuries (12 and 14.6% of total injuries, respectively). The remaining 20.6% were injuries of the trunk, thorax and abdomen. For 28 patients (10.5%) no data were available about the site of injury (Table 1).

The trauma victims reported a median pain level of 8 points (IQR 7 to 9) on the numeric rating scale at the initial assessment by first responders. Nalbuphine caused a statistically significant and clinically relevant decrease in the level of pain, by a median of 3 NRS units, ($p < 0.001$) (Table 1, Figs. 2 & 3). The multivariate regression model showed that pain reduction was more pronounced in patients with higher initial pain levels. This effect decreased but remained statistically significant in the second multivariate model using a relative scale for pain reduction and thereby avoiding heteroscedasticity in the model (Table 2). Nalbuphine was more effective in adolescents than in patients aged 20 to 60 years ($p = 0.006$). The same tendency was observed for the elderly population, (≥ 60 years of age); however, there were only 20 patients in this age group and the difference was not statistically significant. The level of pain reduction was similar for both sexes (Table 2). Forty-one patients (15.3%), expressed dissatisfaction with the treatment.

Mild side effects were reported in 5.6% ($n = 11$) of patients. No major adverse events like intoxications which needed to be reversed by the intravenous administration of naloxon were observed.

Discussion

In our study, the majority of the patients reported a mean reduction of 3 points on the NRS, without any major adverse events, after nalbuphine administration.


The pain relief reported in our study is consistent with the literature, where a decrease of more than 2 points on the NRS was deemed good pain relief [25]. A study with out-of-hospital use of nasal fentanyl also showed an

Table 1 Baseline Characteristics and pain

Variable	Total $n = 267$
Age in years	
Mean, \pm SD	33.3 \pm 18.2
< 20, n (%)	84 (31.5)
20–60, n (%)	163 (61.1)
≥ 60 , n (%)	20 (7.5)
Male sex, n (%)	157 (58.8)
Pain (NRS)	
Initial, median (IQR)	8 (7 to 9)
After nalbuphine	5 (4 to 7)
Missing, n (%)	19 (7.1)
Pain reduction (NRS)	
Median (IQR)	–3 (–4 to –1)
Clinically relevant pain reduction, n (%)	145 (58.5)
Missing, n (%)	19 (7.1)
Dose of Nalbuphine	
5 mg, n (%)	24 (9.0)
10 mg, n (%)	128 (47.9)
15 mg, n (%)	35 (13.1)
20 mg, n (%)	80 (30.0)
Location of Trauma	
Shoulder, n (%)	63 (23.6)
Upper arm, n (%)	22 (8.2)
Elbow, n (%)	1 (0.4)
Forearm or hand, n (%)	32 (12.0)
Hip or femur, n (%)	22 (8.2)
Knee, n (%)	32 (12.0)
Lower leg, n (%)	39 (14.6)
Foot, n (%)	1 (0.4)
Neck, n (%)	0 (0.0)
Back, n (%)	8 (3.0)
Thorax or clavícula, n (%)	18 (6.7)
Abdomen, n (%)	1 (0.4)
Missing, n (%)	28 (10.5)
Adverse Events	
None, n (%)	252 (94.4)
Nausea or vomiting, n (%)	3 (1.1)
Retching, n (%)	5 (1.9)
Nasal discomfort, n (%)	3 (1.1)
Major adverse events, n (%)	0 (0)
Technical device problem, n (%)	4 (1.5)

Footnote:

No missing data if not stated explicitly. SD Standard Deviation, IQR Inter Quartile Range



average reduction of 3 points on the NRS, leading to the conclusion that nasal fentanyl is effective for analgesia in the pre-hospital phase [26].

Only a few studies have evaluated analgesia with nalbuphine in the prehospital setting, and they had conflicting results. When given by paramedics out-of-hospital, IV or IM nalbuphine reduced pain by 5 points on the NRS [27], while the same strategy resulted in excessive morphine requirements after hospital admission in a case series. That study even reported less decline in pain scores after further administration of analgesics in the

emergency department in prehospital nalbuphine patients [28], which is in accordance with a case review that described increased opioid requirements after nalbuphine [18]. In fact, this is expected because of the mixed agonist/antagonist effects of nalbuphine, with agonistic effects on the κ -receptors and antagonistic effects on the μ -receptor [12]. Therefore, if analgesia is continued with pure μ -receptor agonists, an increased dose is needed to overcome the antagonistic effect exerted by nalbuphine. Another possible disadvantage of mixed opioid agonist/antagonists is a limited analgesic effect or




Table 2 Multivariate Linear Regression Models on Pain Reduction after Nasal Nalbuphine

Variable	Absolute NRS reduction model			Relative NRS reduction model (%)		
	Estimate	95% C.I.	p-value	Estimate	95% C.I.	p-value
Age < 20 years	0.0			0.0		
Age 20–60 years	−0.61	−1.11 to −0.10	0.018	−0.87	−14.89 to −2.48	0.006
Age > 60 years	−0.59	−1.54 to 0.36	0.221	−7.77	−19.47 to 3.94	0.193
Male sex	0.0			0.0		
Female sex	0.08	−0.39 to 0.54	0.754	1.16	−4.21 to 7.35	0.594
Initial pain (NRS)	0.51	0.31 to 0.72	< 0.001	2.53	0.03 to 5.04	0.048

Complete-case analysis: Included observations $n = 244$, 19 missing observations. Estimate = Difference in NRS reduction after application of nasal Nalbuphine according to either level of the factor variable or initial pain level (absolute difference or relative difference in percentage respectively). 95% C.I. = 95% confidence interval of the estimate. Male sex and Age < 20 years served as the reference groups in both models

ceiling effect [12]. This could explain why no patient was completely free of pain after nalbuphine, with a minimum NRS of one after treatment. We did not find any significant differences between sexes regarding pain intensity before or after nalbuphine, regardless of the administered dose. There is some evidence that nalbuphine has a pain-facilitating effect in males, at least if it is administered in small doses of 5 mg [29], an effect we did not observe. There was a predominance of males in our study (58.8% vs. 41.2%) which is consistent with the average distribution of injured people on Swiss ski slopes (56.6% male vs. 43.4% female) [30]. We observed only a few minor side effects in our patients. Although unlikely, the risk of respiratory depression, monitored by pulse oximetry and respiratory rate, also exists following nalbuphine [12, 16, 17], but this was not reported in our study. Interestingly, in our study only 15% of trauma patients reported dissatisfaction with nalbuphine, and though the number of patients who reported a good analgesic effect was high (60.0%). This phenomenon was already described in labouring women treated with nalbuphine: only 54–57% of the parturient women experienced good pain relief, but 78% were willing to have the same treatment in a subsequent birth [15]. This could possibly be explained by a reported feeling of relaxation, rather than pain relief [15].

There is also evidence that satisfaction with opioid treatment seems to be influenced, at least in part, by rapid onset [16]. Nasally administered drugs are normally well absorbed, with rapid onset of action due to the rich blood supply and large surface of the mucosa, bypassing of a first-pass-effect and, maybe at least in part bypassing the blood-brain-barrier [21].

Our study has some limitations. First, we could not follow up patients after handover to EMS/HEMS personnel. Second, we mainly observed traumatic shoulder and knee injuries, which is expected with the predominance of our study sites being in Swiss ski resorts [30]. Third, there could be a bias in data collection because it was performed directly by first responders. If a

patient felt sympathies for his rescuer, it is possible that the answers have been whitewashed, in particular regarding qualitative outcomes such as overall satisfaction. Fourth, although the qualitative pain reduction was reported for each patient, there were missing NRS values after nalbuphine in 10.5% ($n = 28$) of the patients, which is to be expected in an observational study in the pre-hospital setting. There was also a predominance of the male sex, which could have had an influence on the described pain reduction. We observed only a few minor side effects with nalbuphine. However, we did not follow up on the patients, and we cannot prove that nalbuphine administration is always safe.

In conclusion, nasal nalbuphine administered by first responders was a noninvasive pain management strategy that provided effective and presumably safe analgesia in prehospital, acutely injured patients in our studied environment. This method may provide an alternative, especially in situations involving severe pain and prolonged time between arrival of the first responders and arrival of EMS/HEMS personnel on scene. This conclusion is viable in the setting described, involving trained first responders. Further studies would be needed to include an overall recommendation for laypersons.

Abbreviations

CI: Confidence interval; CNS: Central nervous system; Da: Dalton; EMS: Emergency medical service, ambulance service; HEMS: Helicopter emergency medical service; i.m.: Intramuscular; i.v.: Intravenous; NRS: Numeric rating scale; s.c.: Subcutaneous; SD: Standard deviation

Acknowledgements

We are indebted to the first responders in our study for their efforts and contributions.

We would like to thank Jeannie Wurz, Medical Editor, Bern, Switzerland, for editorial assistance.

Authors' contributions

RA, D.S. and U.P. developed the original idea for this study and drafted the manuscript. Y.B., L.T., and V.W. critically revised the manuscript, gathered additional data, and made important recommendations. L.M. conducted the statistical analysis and critically revised the manuscript. All authors read and agreed to the final version of the manuscript.

Funding

No external funding.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

The local ethical committee evaluated the study and waived written informed consent (KEK 2019–01444).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Anaesthesiology and Intensive Care Medicine, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, 9007 St. Gallen, Switzerland. ²Swiss Air-Ambulance, Rega (Rettungsflugwacht / Garde Aérienne), Zürich, Switzerland. ³Department of Emergency Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010 Bern, Switzerland. ⁴Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. ⁵Schutz & Rettung Zürich, Zürich, Switzerland. ⁶Department of Anaesthesiology, Cantonal Hospital Aarau, Aarau, Switzerland. ⁷Department of Anaesthesiology and Intensive Care Medicine, Friedrichshafen Regional Hospital, Friedrichshafen, Germany. ⁸Department of Vascular Surgery, University Hospital Zürich, Zürich, Switzerland. ⁹Department of Anaesthesiology, Klinik Gut, St. Moritz, Switzerland.

Received: 5 November 2020 Accepted: 5 February 2021

Published online: 17 February 2021

References

- Galinski M, Ruscev M, Pommerie F, Hubert G, Srij M, Lapostolle F, Adnet F. Prise en charge de la douleur aiguë sévère chez l'adulte en médecine extrahospitalière: enquête nationale auprès des médecins de Smur. National survey of emergency management of acute pain in prehospital setting. *Annales Françaises d'Anesthésie et de Réanimation*. 2004;23:1149–54.
- Borland ML, Jacobs I, Rogers IR. Options in prehospital analgesia. *Emerg Med*. 2002;14:77–84.
- Chambers JA, Guly HR. The need for better pre-hospital analgesia. *Arch Emerg Med*. 1993;10:187–92.
- Benov AMD, et al. Battlefield pain management. *J Trauma Acute Care Surg*. 2017;83(Issue 1):S150–5.
- de Rocquigny GMD, et al. Use of ketamine for prehospital pain control on the battlefield: A systematic review. *J Trauma and Acute Care Surg*. 2020; 88(Issue 1):180–5.
- Wedmore IS, et al. Safety and efficacy of oral transmucosal fentanyl citrate for prehospital pain control on the battlefield. *J Trauma Acute Care Surg*. 2012;73(Issue 6):S490–5.
- Ellerton J, Milani M, Blancher M, Zen-Ruffinen G, Skaiaa SC, Brink B, Lohani A, Paal P. Managing moderate and severe pain in mountain rescue. *High Alt Med Biol*. 2014;15(1):8–14.
- Ellerton JA, Greene M, Paal P. The use of analgesia in mountain rescue casualties with moderate or severe pain. *Emerg Med J*. 2013;30(6):501–5.
- Lischke V, et al. Bergrettung im Wandel der Zeit – 100 Jahre Bergwacht in Deutschland. *Der Notarzt*. 2020;36(06):336–45.
- Hörhager K, Gehrig M, Keller P, et al. Schweizerische Rettungsflugwacht Rega. 2019. https://www.rega.ch/fileadmin/seiteninhalt/Aktuell/Jahresbericht/Jahresbericht_2018_de.pdf. Accessed 7.9.2020.
- Bianchi G, Brügger O. Unfallgeschehen beim Ski- und Snowboardfahren in der Schweiz: Unfallausmass, Risikoabschätzung und Entwicklung. Bern: bfu - Beratungsstelle für Unfallverhütung; 2016. bfu-Grundlagen.
- Errick JK, Heel RC. Nalbuphine – a preliminary review of its pharmacological properties and therapeutic efficacy. *Drugs*. 1983;26:191–211.
- Fachinformation des Arzneimittel-Kompodium der Schweiz. Nalbuphin OrPha. Online version published September 17, 2009. Fachinformation des Arzneimittel-Kompodium der Schweiz. Nalbuphin OrPha Online version published September 17, 2009. <https://compendium.ch/mpro/mnr/14977/html/de> [accessed on 16 May 2019].
- Jacqz-Aigrain E, Serreau R, Boissinot C, et al. Excretion of Ketoprofen and Nalbuphine in human Milk during treatment of maternal pain after delivery. *Ther Drug Monit*. 2007;29:815–8.
- Nicolle E, Devillier P, Delanoy B, et al. Therapeutic monitoring of nalbuphine: transplacental transfer and estimated pharmacokinetics in the neonate. *Eur J Clin Pharmacol*. 1996;49:485–9.
- Dinges HC, Otto S, Stay DK, et al. Side Effect Rates of Opioids in Equianalgesic Doses Via Intravenous Patient-Controlled Analgesia. *Anesth Analg*. 2018.
- Mazak K, Hosztafi S, Kraszni M, Noszal B. Physico-chemical profiling of semisynthetic opioids. *J Pharm Biomed Anal*. 2017;135:97–105.
- Houlihan KPG, Mitchell RG, Flapan AD, et al. Excessive morphine requirements after pre-hospital Nalbuphine analgesia. *J Accid Emerg Med*. 1999;16:29–31.
- Schultz-Machata AM, Becke K, Weiss M. Nalbuphin in der Kinderanästhesie. *Anaesthesist*. 2014;63:135–43.
- Piffner M, Gotta V, Berger-Olah E, et al. P78 pharmacokinetics of intravenous and intranasal nalbuphine in infants. *Arch Dis Child*. 2019;104:e49.
- Bhise SB, Yadav AV, Makrand Avachat A, Malayandi R. Bioavailability of intranasal drug delivery system. *Asian Journal of Pharmaceutics*. 2008;Oct-Dec:201–15.
- RD G. Intranasal drug delivery for children with acute illness. *Current Drug Therapy*. 2006;1:127–30.
- Talegonkar S, Mishra PR. Intranasal delivery: an approach to bypass the blood brain barrier. *Ind J Pharmacol*. 2004;36:140–7.
- HD K. Enhanced delivery of L Dopa by the administration of its prodrug via nasal route. Ph. D thesis. Lexington, Kentucky: University of Kentucky; 1995.
- Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. *J Pain Symptom Manag*. 2003;25(5): 406–11. [https://doi.org/10.1016/s0885-3924\(03\)00162-3](https://doi.org/10.1016/s0885-3924(03)00162-3).
- Karlsen A, Pedersen D, Trautner S, et al. Safety of intranasal fentanyl in the out-of-hospital setting: a prospective observational study. *Ann Emerg Med*. 2014;63:699–703.
- Chambers JA, Guly HR. Prehospital intravenous Nalbuphine administered by paramedics. *Resuscitation*. 1994;27:153–8.
- Robinson N, Burrows N. Excessive morphine requirements after pre-hospital nalbuphine analgesia. *J Accid Emerg Med*. 1999;16:392.
- Gear R, Becerra L, Upadhyay J, Bishop J, Wallin D, et al. Pain facilitation brain regions activated by Nalbuphine are revealed by pharmacological fMRI. *PLoS One*. 2013;8(1):e50169. <https://doi.org/10.1371/journal.pone.0050169>.
- Niemann S, Achermann Stürmer Y, Bürgi F, et al. bfu – Beratungsstelle für Unfallverhütung. STATUS 2018: Statistik der Nichtberufsunfälle und des Sicherheitsniveaus in der Schweiz. Strassenverkehr, Sport, Haus und Freizeit. Bern: bfu; 2018. ISSN 1663-78

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

